ReportWire

Tag: Health care industry

  • Twitter Blue signups unavailable after raft of fake accounts

    Twitter Blue signups unavailable after raft of fake accounts

    [ad_1]

    Twitter’s relaunched premium service — which grants blue-check “verification” labels to anyone willing to pay $8 a month — was unavailable Friday after the social media platform was flooded by a wave of imposter accounts it itself had approved.

    It’s the latest whiplash-inducing change to the service where uncertainty has become the norm since billionaire Elon Musk took control two weeks ago. Prior to that, the blue check was granted to government entities, corporations, celebrities and journalists verified by the platform — precisely to prevent impersonation. Now, anyone can get one as long as they have a phone, a credit card and $8 a month.

    An impostor account posing as pharmaceutical giant Eli Lilly & Co. and registered under the revamped Twitter Blue system tweeted that insulin was free, forcing the Indianapolis company to post an apology. Nintendo, Lockheed Martin, Musk’s own companies Tesla and SpaceX were also impersonated, as well as the accounts of various professional sports and political figures.

    For advertisers who have put their business with Twitter on hold, the fake accounts could be the last straw: Musk’s rocky run atop the platform — laying off half its workforce and triggering high-profile departures — has raised questions about its survivability.

    The impostors can cause big problems, even if they’re taken down quickly.

    They have created “overwhelming reputational risk for placing advertising investments on the platform,” said Lou Paskalis, longtime marketing and media executive and former Bank of America head of global media. Adding that with the fake “verified” brand accounts, “a picture emerges of a platform in disarray that no media professional would risk their career by continuing to make advertising investments on, and no governance apparatus or senior executive would condone if they did.”

    Adding to the confusion, Twitter now has two categories of “blue checks,” and they look identical. One includes the accounts verified before Musk took helm. It notes that “This account is verified because it’s notable in government, news, entertainment, or another designated category.” The other notes that the account subscribes to Twitter Blue.

    But as of midday Friday, Twitter Blue was not available for subscription.

    On Thursday, Musk tweeted that “too many corrupt legacy Blue ‘verification’ checkmarks exist, so no choice but to remove legacy Blue in coming months.”

    An email sent to Twitter’s press address went unanswered. The company’s communications department was gutted in the layoffs and Twitter has not responded to queries from The Associated Press since Oct. 27 when Musk took the helm.

    Thursday night, Twitter also once again began adding gray “official” labels to some prominent accounts. It had rolled out the labels earlier this week, only to kill them a few hours later.

    They returned Thursday night, at least for some accounts — including Twitter’s own, as well as big companies like Amazon, Nike and Coca-Cola, before many vanished again.

    Celebrities also did not appear to be getting the “official” label.

    Twitter is heavily dependent on ads and about 90% of its revenue comes from advertisers. But each change that Musk is rolling out — or rolling back — makes the site less appealing for big brands.

    “It has become chaos,” said Richard Levick, CEO of public relations firm Levick. “Who buys into chaos?”

    A bigger issue for Musk might be the risk to his reputation as a model tech executive, since the rollout of different types of verifications and other changes have been botched, Levick added.

    “It’s another example something not very well thought out, and that’s what happens when you rush,” Levick said. “Musk has been known as a trusted visionary and magician — he can’t lose that moniker and that’s what’s at risk right now,” Levick said.

    Twitter is a small part of total ad spending for the biggest companies that advertise on the platform. Google, Amazon and Meta account for about 75% of digital ads globally, with all other platforms combined making up the other 25%. Twitter accounts for about 0.9% of global digital ad spending, according to Insider Intelligence.

    “For most marketers on budgets, Twitter has always been that thing that is potentially too big to totally ignore but not quite big enough to care about,” said Mark DiMassimo, creative chief of marketing agency DiGo.

    “None of this is a forever moral or ethical stand on the point of advertisers,” he added. “If Musk proves to be a civilizing force in the long run advertisers will come back — if Twitter is still there. It’s a ‘for now’ decision — why be there now?”

    ———

    AP Technology Writer Frank Bajak in Boston contributed to this report.

    [ad_2]

    Source link

  • Twitter Blue signups unavailable after raft of fake accounts

    Twitter Blue signups unavailable after raft of fake accounts

    [ad_1]

    Twitter’s relaunched premium service — which grants blue-check “verification” labels to anyone willing to pay $8 a month — was unavailable Friday after the social media platform was flooded by a wave of imposter accounts approved by Twitter.

    Before billionaire Elon Musk took control of the social media platform two weeks ago the blue check was granted to celebrities, journalists and verified by the platform — precisely to prevent impersonation. Now, anyone can get one as long as they have a phone, a credit card and $8 a month.

    After an imposter account registered under the revamped Twitter Blue system tweeted that insulin was free, pharmaceutical giant Eli Lilly & Co. had to post an apology. Nintendo, Lockheed Martin, Musk’s own Tesla and SpaceX were also impersonated as well as the accounts of various professional sports figures.

    For advertisers who have put their business in Twitter on hold, the fake accounts could be the last straw as Musk’s rocky run atop the platform — laying off half the workforce and triggering high-profile departures — raises questions about its survivability.

    There are now two categories of “blue checks,” and they look identical. One includes the accounts verified before Musk took helm. It notes that “This account is verified because it’s notable in government, news, entertainment, or another designated category.” The other notes that the account subscribes to Twitter Blue.

    An email sent to Twitter’s press address went unanswered. The company’s communications department was gutted in the layoffs.

    On Thursday, Musk tweeted that “too many corrupt legacy Blue ‘verification’ checkmarks exist, so no choice but to remove legacy Blue in coming months.”

    Twitter Blue was not available on the platform’s online version, which said signup was only possible on the iPhone version. But the iPhone version did not offer Twitter Blue as an option

    Twitter also once again began adding gray “official” labels to some prominent accounts. It had rolled out the labels earlier this week, only to kill them a few hours later.

    They returned Thursday night, at least for some accounts — including Twitter’s own, as well as big companies like Amazon, Nike and Coca-Cola, before many vanished again.

    Celebrities also did not appear to be getting the “official” label.

    AP Technology Writer Frank Bajak in Boston contributed to this report.

    [ad_2]

    Source link

  • Lab-grown blood given to humans in world-first trial aimed at combatting rare disorders

    Lab-grown blood given to humans in world-first trial aimed at combatting rare disorders

    [ad_1]

    Blood grown in a laboratory has been transfused into humans for the first time in a landmark clinical trial.

    Future Publishing | Future Publishing | Getty Images

    LONDON — Blood grown in a laboratory has been transfused into humans for the first time in a landmark clinical trial that U.K. researchers say could significantly improve treatment for people with blood disorders and rare blood types.

    Two patients in the U.K. received tiny doses — equivalent to a few teaspoons — of the lab-grown blood in the first stage of a wider trial designed to see how it behaves inside the body.

    The trial, which will now be extended to 10 patients over the course of several months, aims to study the lifespan of lab-grown cells compared with infusions of standard red blood cells.

    Researchers say the aim is not to replace regular human blood donations, which will continue to make up the majority of transfusions. But the technology could allow scientists to manufacture very rare blood types which are difficult to source but which are vital for people who depend on regular blood transfusions for conditions such as sickle cell anemia.

    “This world leading research lays the groundwork for the manufacture of red blood cells that can safely be used to transfuse people with disorders like sickle cell,” said Dr. Farrukh Shah, medical director of Transfusion for NHS Blood and Transplant, one of the collaborators on the project.

    “The need for normal blood donations to provide the vast majority of blood will remain. But the potential for this work to benefit hard to transfuse patients is very significant,” she added.

    How does the technology work?

    The research, which was conducted by researchers in Bristol, Cambridge and London, as well as NHS Blood and Transplant, focuses on red blood cells that carry oxygen from the lungs to the rest of the body.

    Initially, a regular donation of blood was taken and magnetic beads were used to detect flexible stem cells that are capable of becoming red blood cells.

    Those stems were then placed in a nutrient solution in a laboratory. Over the course of around three weeks, the solution encouraged those cells to multiply and develop into more mature cells.

    The cells were then purified using a standard filter — the same kind of filter that is used when regular blood donations are processed to remove white blood cells — before being stored and later transfused into the patients.

    For the trial, the lab-grown blood was tagged with a radioactive substance, often used in medical procedures, to monitor how long it lasts in the body.

    The same process will now be applied for a trial of 10 volunteers, who will each receive two donations of 5-10mls at least four months apart — one of normal blood and one of lab-grown blood — to compare the cells’ lifespans.

    How much will it cost?

    It is also hoped that a superior lifespan of lab-grown cells could mean patients require fewer transfusions over time.

    A typical blood donation contains a mixture of young and old red blood cells, meaning their lifespan can be unpredictable and sub-optimal. Lab-grown blood, meanwhile, is freshly made, meaning it should last the 120 days expected of red blood cells.

    Still, there are significant costs currently attached to the technology.

    The average blood donation currently costs the NHS around £145, according to NHS Blood and Transplant. Lab-grown substitutes would likely be more expensive.

    NHS Blood and Transplant said there was “no figure” for the procedure as yet, but added that costs would be reduced as the technology is scaled up.

    “If the trial is successful and the research works, then it could be introduced at scale in future years, meaning that costs would fall,” a spokesperson told CNBC.

    [ad_2]

    Source link

  • China posts 6-month high Covid count as it sticks with strategy

    China posts 6-month high Covid count as it sticks with strategy

    [ad_1]

    A health worker wears a protective suit near a testing booth as outbreaks of coronavirus disease (COVID-19) continue in Beijing, China, Oct. 23, 2022.

    Thomas Peter | Reuters

    China on Sunday reported its highest number of new Covid-19 infections in six months, a day after health officials said they were sticking with strict coronavirus curbs, likely disappointing recent investor hopes for an easing.

    China recorded 4,420 new locally transmitted Covid-19 infections on Saturday, the National Health Commission said, the most since May 6 and compared up from 3,659 new local cases a day earlier.

    While case numbers are extremely low by global standards, China has stuck with a zero-Covid approach nearly three years into the pandemic that involves lockdowns, quarantines, frequent testing and a drastic decrease in inbound travel.

    At a news conference on Saturday, health officials reiterated their commitment to the “dynamic-clearing” approach to Covid cases as soon as they emerge.

    China’s anti-Covid measures are “completely correct, as well as the most economical and effective”, said disease control official Hu Xiang. “We should adhere to the principle of putting people and lives first, and the broader strategy of preventing imports from outside and internal rebounds.”

    Chinese stocks soared last week on rumors of a possible easing of the Covid curbs, and media reports that some tweaks to policy could be coming soon.

    However, many analysts have said they do not expect significant easing to begin until after China’s annual parliamentary session in March.

    Goldman Sachs analysts said Saturday’s announcement showed “the government still needs to keep its zero-Covid policy until all preparations are done. This may take a few months, in our view,” they wrote, saying their “baseline” expectation was for a reopening in the April-June quarter.

    The southern city of Guangzhou continued to report rising infections, with 66 new locally transmitted symptomatic and 1,259 asymptomatic cases, compared with 111 symptomatic and 635 asymptomatic cases a day before, authorities in the city of nearly 19 million people said.

    China’s capital Beijing reported 43 symptomatic and six asymptomatic cases, compared with 37 symptomatic and five asymptomatic cases the previous day.

    Still, the annual Beijing marathon took place on Sunday morning under strict Covid protocols, after being cancelled the previous two years.

    Some 26,000 participants registered for the event that began under smoggy skies in central Beijing’s Tiananmen Square. Runners were required to take PCR tests for the three days leading up to the race and not to leave Beijing for seven days.

    [ad_2]

    Source link

  • Magic mushroom compound psilocybin can help treat depression, study finds

    Magic mushroom compound psilocybin can help treat depression, study finds

    [ad_1]

    The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type ever conducted.

    David Buzzard – media-centre.ca / Getty Images

    LONDON — The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type ever conducted.

    Psilocybin was given to 233 patients who had already tried at least two antidepressants in the past with little success, suggesting the compound could have huge benefits for those suffering with hard-to-treat depression.

    After receiving the psilocybin, patients entered a “walking dream-like” state for between four and six hours and then left the clinic once they had returned to their normal state.

    The trial found that a 25mg dose of psilocybin, given alongside psychological support, triggered a reduction in levels of depression three weeks after treatment.

    The study, published Thursday in the New England Journal of Medicine, was carried out internationally by London-based COMPASS Pathways.

    Around 100 million people worldwide suffer with depression that is resistant to treatment, and so the findings of the study are a step in the right direction, according to James Rucker, consultant psychiatrist and senior clinical lecturer at King’s College London, who was involved in the study.

    “Our task now is to investigate psilocybin for treatment-resistant depression in larger trials with more participants, comparing it both to placebo and to established treatments,” Rucker said, according to a King’s College London press release

    The drugs were trialed in doses of 1mg, 10mg and 25mg and adverse effects recorded across all groups included headaches, nausea and thoughts around suicide.

    There was not, however, an equal number of “severely depressed” participants in each dosage group, according to Ravi Das, an associate professor at the University College London Institute of Mental Health, which “does not appear to be acknowledged in the paper,” as reported by Reuters.

    Critics have also expressed concern that this could lead to a rise in usage of magic mushrooms in non-pharmaceutical settings.

    [ad_2]

    Source link

  • Pfizer raises 2022 earnings guidance, beats third-quarter expectations

    Pfizer raises 2022 earnings guidance, beats third-quarter expectations

    [ad_1]

    Vials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022.

    Rodrigo Garrido | Reuters

    Pfizer on Tuesday raised its 2022 earnings guidance after booking a strong third quarter that beat Wall Street expectations.

    Pfizer now expects earnings per share of $6.40 to $6.50 for the year, up from its previous forecast of $6.30 to $6.45. The pharmaceutical company also raised the lower end of its sales guidance and now expects revenues of $99.5 billion to $102 billion for the year.

    Pfizer raised its full year sales guidance for its Covid-19 vaccine to $34 billion this year, up $2 billion from the company’s previous expectations. The company is maintaining its revenue expectations of $22 billion for the antiviral pill Paxlovid.

    Its shares rose by about 4% in premarket trading.

    Here’s how the company performed compared with what Wall Street expected for the third quarter, based on analysts’ average estimates compiled by Refinitiv:

    • Adjusted EPS: $1.78 per share vs. $1.39 expected
    • Revenues: $22.6 billion vs. $21 billion expected

    Pfizer’s sold $4.4 billion of its Covid vaccine worldwide in the quarter, a decrease of 66% compared to the same period last year. It sold $7.5 billion of the Paxlovid treatment during the quarter that ended Sept. 30.

    Pfizer booked net income of $8.6 billion for the third quarter, a 6% increase over the same quarter last year.

    Pfizer CEO Albert Bourla indicated that company is looking beyond the Covid pandemic which has led to record windfalls for the pharmaceutical giant.

    Bourla said in a statement that Pfizer plans to launch 19 new products or new uses for existing drugs in the next 18 months. The company, for example, reported positive clinical trial data Tuesday for its maternal RSV vaccine that protects newborns.

    The RSV vaccine is administered as a single dose to the mother in the late second or third trimester of her pregnancy. Pfizer’s data showed that in the first 90 days of the baby’s life, the vaccine was 81% effective at preventing severe lower respiratory tract illnesses that require hospitalization or assisted breathing.

    This is breaking news. Please check back for updates.

    [ad_2]

    Source link

  • CDC is discussing using oral polio vaccine for first time in 20 years to stop New York outbreak

    CDC is discussing using oral polio vaccine for first time in 20 years to stop New York outbreak

    [ad_1]

    The Centers for Disease Control and Prevention is considering using the oral polio vaccine for the first time in more than 20 years to stop an outbreak in the greater New York City metropolitan area that left an adult paralyzed over the summer.

    “We are in discussions with our New York State and New York City colleagues about the use of nOPV,” said Dr. Jannell Routh, the CDC’s team leader for domestic polio, referring to the novel oral polio vaccine.

    “It will be a process. It’s not something that we can pull the trigger on and have it appear overnight,” Routh told CNBC. “There will be lots of thought and discussion about the reintroduction of an oral polio vaccine into the United States,” she said.

    The New York State Department of Health, in a statement, said it is collaborating with the CDC on potential future options to respond to the outbreak.

    U.S. drug regulators pulled the oral vaccine off shelves in 2000 because it contains a live — but weakened — strain of the virus that can, in rare circumstances, mutate into a virulent form that is contagious and potentially paralyze people who are not vaccinated.

    Scientists believe this latest outbreak was caused by someone who was vaccinated with the live virus overseas and started a chain of transmission that eventually found its way to the U.S. Sewage samples in New York are linked to earlier samples in London and Jerusalem. It’s unclear where the transmission began originally. While the oral vaccine doesn’t normally cause polio that paralyzes people, this one did because it was able to mutate into more virulent strains while spreading across among people who weren’t vaccinated.

    The U.S. currently uses the inactivated polio vaccine which is administered as a shot and contains chemically killed virus that cannot replicate, mutate or cause disease. While New York state health officials have launched an immunization drive with the inactivated polio shots, that vaccine hasn’t stopped this outbreak.

    The CDC has set up a work group within its committee of independent vaccine advisors to develop criteria for when the novel oral polio vaccine might need to be used to stop the current outbreak in the New York City area and potential future ones. The work group met publicly for the first time on Wednesday.

    “Since this outbreak occurred in New York, it was determined that we need to revisit polio. It’s really that simple,” said Dr. Oliver Brooks, the workgroup chairperson and chief medical officer at Watts Healthcare in Los Angeles.

    The problem is that although the inactivated vaccine is highly effective at preventing paralysis, it does not stop transmission of the virus. The oral polio vaccine is much more effective at stopping transmission of the virus and is normally used to quash outbreaks.

    The poliovirus strain currently circulating in the New York City metro area mutated from and is genetically linked to the Sabin Type 2 strain used in an older version of the oral polio vaccine.

    The U.S., if needed, would use the novel oral polio vaccine which is a safer and newer version that is more stable and carries a much lower risk of mutating into a virus strain that can spread and cause disease in people who are unvaccinated.

    The novel oral polio vaccine was developed to stop poliovirus outbreaks caused by the less stable older version of the vaccine, according to the Global Polio Eradication Initiative. More than 450 million doses have been administered in 21 countries around the world.

    Any decision to use the novel oral polio vaccine would require either an approval or emergency use authorization from the Food and Drug Administration. CNBC has reached out to FDA for comment.

    An unvaccinated adult in Rockland County, New York was paralyzed in June after contracting poliovirus. It was the first known U.S. case in nearly a decade and the first in New York since 1990. There have been no further cases of paralysis so far, though New York state health officials have warned that unvaccinated people are at serious risk and should get up to date on their shots immediately.

    New York State Department of Health has detected poliovirus in sewage dating back to April and as recently as September in several counties in the New York City area. The virus has been detected in 70 sewage samples across Rockland, Sullivan, Orange, Nassau, Kings and Queens counties.

    The U.S. was declared polio free in 1979.

    New York Gov. Kathy Hochul declared a state of emergency in September and Health Commissioner Dr. Mary Bassett declared the spread of poliovirus an imminent threat to public health.

    [ad_2]

    Source link

  • Uninsured kids will still receive Covid vaccines for free after shots move to commercial market

    Uninsured kids will still receive Covid vaccines for free after shots move to commercial market

    [ad_1]

    A child is administered a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) pediatric vaccine.

    Mayela Lopez | Reuters

    The Centers for Disease Control and Prevention took a major step Wednesday toward ensuring that kids who are uninsured can receive Covid-19 vaccines for free after the federal government shifts its immunization program to the commercial market.

    The CDC’s independent advisors voted unanimously on Wednesday to include Covid shots authorized for kids by the Food and Drug Administration in the federal government’s Vaccines For Children program.

    The Vaccines for Children program provides vaccines to kids under age 19 whose families cannot afford them. Children are eligible for the program if they qualify for Medicaid or are uninsured, underinsured or Native American.

    Including Covid shots in the program does not make them a routine childhood vaccination for school, said Dr. Jose Romero, director of the National Center for Immunization and Respiratory Diseases.

    The U.S. government has been providing Covid vaccines to everyone in the U.S. for free during the pandemic. But the Biden administration is working on a plan to transition the vaccination program to the commercial market as soon as 2023, which means people will have to start paying for the shots.

    Dr. Jeanne Santoli, a CDC official, said the public health agency will start awarding contracts for healthcare providers to give the Covid shots for free to uninsured kids.

    Currently, children as young as six months old are eligible for Pfizer’s and Moderna’s two-dose primary series with the first-generation shots that target the original Covid strain. Kids as young as age 5 are eligible for the new booster shots that target the dominant omicron BA.5 subvariant.

    The decision to include Covid shots in the free vaccine program will prove crucial to maintaining access for many children. As many as 5.3 million kids are expected to lose health insurance through Medicaid or the Children’s Health Insurance Program whenever the Biden administration decides to end the Covid public health emergency, according to the Health and Human Services Department.

    “This is an access issue. This is an issue to allow children that don’t have insurance to gain access to this vaccine,” said Romero.

    Although Covid is generally less severe in kids than adults, more than 162,000 children under age 18 have been hospitalized with Covid since August 2020, according to data from the CDC. More than 1,800 children have died from Covid since the pandemic began, according to the data.

    Public health officials are also worried about kids developing long Covid even after a mild infection.

    CNBC Health & Science

    Read CNBC’s latest global health coverage:

    [ad_2]

    Source link

  • 3 takeaways from our daily meeting: Banks as market leaders, 3 trades and keeping CRM

    3 takeaways from our daily meeting: Banks as market leaders, 3 trades and keeping CRM

    [ad_1]

    [ad_2]

    Source link

  • Omicron BA.5 is declining in the U.S. as emerging variants gain ground, CDC data shows

    Omicron BA.5 is declining in the U.S. as emerging variants gain ground, CDC data shows

    [ad_1]

    The U.S. faces at least seven different versions of Covid-19 omicron as the nation heads into winter when health officials are expecting another wave of viral infections.

    Although the omicron BA.5 variant remains dominant in the country, it is starting to lose some ground to other versions of the virus, according to data from the Centers for Disease Control and Prevention published on Friday.

    Omicron BA.5 has splintered into several new but related variants that include BQ.1, BQ.1.1 and BF.7. The U.K. Health Security Agency, in a report earlier this month, said these three variants are demonstrating a growth advantage over BA.5, which was the most contagious version to date.

    In the U.S., omicron BA.5 makes up about 68% of all new infections, down from about 80% at the beginning of October. BQ.1, BQ.1.1 and BF.7 are now causing about 17% of new infections combined, according to the CDC data.

    About 3% of new infections are attributable to BA.2.75. and BA.2.75.2, which are related to the omicron BA.2 variant that caused a bump in cases during the spring but was pushed out.

    Scientists at Peking University in China found that omicron BA.2.75.2 and BQ.1.1 were the most adept at evading immunity from prior BA.5 infection and several antibody drugs. The study, published earlier in October, has not been peer reviewed.

    Dr. Ashish Jha, the White House Covid response coordinator, said earlier this week that U.S. health officials are closely monitoring these variants because they are good at evading prior immunity.

    “The reason we’re tracking them is because they either have a lot more immune invasiveness or they render many of our treatments ineffective,” Jha said. “Those are the two major things that get our attention.”

    But Jha said the new omicron boosters that the U.S. started rolling out last month should provide better protection than the first-generation vaccines against these emerging variants. The boosters target BA.5 and the emerging variants are all omicron and most descend from BA.5.

    Jha called on all eligible Americans to get the new boosters by Halloween so they will have full protection for Thanksgiving when family holiday gatherings kick into full swing.

    But the scientists at Peking University said the immune evasiveness of variants like BA.2.75.2 and BQ.1.1 could mean that the BA.5 booster shots will not provide sufficiently broad protection.

    It’s unclear how much more effective the boosters will prove in the real world. The Food and Drug Administration authorized the shots without direct human data, relying instead on clinical trials from a similar shot that was developed against the original version of omicron, BA.1.

    Pfizer and BioNTech on Thursday published the first human data from their BA.5 shots. They triggered a significant boost to the immune system against omicron BA.5 in a lab study that looked at blood samples from adults ages 18 and older, the companies said.

    [ad_2]

    Source link

  • Risk of Covid death almost zero for people who are boosted and treated, White House Covid czar says

    Risk of Covid death almost zero for people who are boosted and treated, White House Covid czar says

    [ad_1]

    People who stay up to date on their vaccines and receive treatments when they have breakthrough infections face almost no risk of dying from Covid-19, a top health official said on Tuesday.

    Dr. Ashish Jha, head of the White House Covid task force, said the U.S. has made major strides in fighting Covid since the early days of the pandemic when thousands of people were dying daily from the virus.

    “If you are up to date with your vaccines and if you get treated if you have a breakthrough infection, your risk of dying from Covid is now close to zero,” Jha told reporters at the White House.

    More than 300 people are still dying every day from Covid on average, according to data from the Centers for Disease Control and Prevention.

    Jha told reporters last week that 70% of the people dying from the virus are 75 and older and don’t have the latest shots or aren’t getting treated as needed. He said this level of death is unacceptable given all the tools the U.S. now has at its disposal to manage the virus.

    Jha encouraged people who have Covid symptoms to get tested so they can get diagnosed and receive treatments such as the antiviral pill Paxlovid when needed.

    “Treatments which we have available today for free keep people out of the hospital, keep people out of the ICU, prevent the worst outcome at all,” Jha said.

    People older than 50 and those who are otherwise at elevated risk, such as people with weak immune systems or serious medical conditions, should be seriously considered for treatments, he said.

    The U.S. rolled out new booster shots that target the dominant omicron BA.5 subvariant in September. Although there’s no real-world data on their effectiveness yet, Jha said they should provide a much higher degree of protection based on what scientists know about how the human immune system works.

    Health officials are expecting Covid infections to increase in November through January as they have every fall and winter since the pandemic began, Jha said. But it’s difficult to predict whether the U.S. will face another major Covid surge because the virus continues to evolve, he added.

    “We are not helpless against these challenges. What happens in the weeks and months ahead will have a large impact on how the winter goes and really what happens this winter is largely up to us as the American people,” Jha said on Tuesday.

    He called on everyone ages 12 and older to get their new Covid booster shot by Halloween so they have protection in time for Thanksgiving when the holiday season gets into full swing. Everyone who is eligible should go out and get their annual flu shot as well because health officials are expecting a significant flu season for the first time since the pandemic began, he said.

    One caveat is people who recently caught Covid can wait three months to get their booster because infection also boosts your immunity, Jha said.

    “Don’t wait — get your new flu shot and your new Covid shot today,” Jha said. “If Americans did that we could save hundreds of lives each day this winter.”

    [ad_2]

    Source link

  • NFL commissioner says league to make ‘change or two’ to concussion protocol

    NFL commissioner says league to make ‘change or two’ to concussion protocol

    [ad_1]

    Roger Goodell, commissioner of the National Football League, testifies remotely during the House Oversight and Reform Committee hearing titled Tackling Toxic Workplaces: Examining the NFLs Handling of Workplace Misconduct at the Washington Commanders, in Rayburn Building on Wednesday, June 22, 2022.

    Tom Williams | Cq-roll Call, Inc. | Getty Images

    The NFL is prepared “to make a change or two” to its concussion protocol, NFL Commissioner Roger Goodell said at a fan forum in London on Saturday as the league faces questions about how the Miami Dolphins handled quarterback Tua Tagovailoa’s recent injuries.

    Responding to a fan’s question about concussions and “recent incidents,” Goodell outlined the league’s “intensive focus” on the issue over the past 15 years and said its medical protocols have served as templates for other sports.

    “Our job really is to continue to modify those as medical experts or other experiences tell you this is something you can do differently,’” he said.

    The commissioner took questions only from fans in London ahead of Sunday’s game between the Green Bay Packers and the New York Giants at Tottenham Hotspur Stadium. He wasn’t made available to the media Saturday. The league did not elaborate on what the potential protocol changes are or when they could come into effect.

    Earlier this week, the NFL Players Association fired the unaffiliated neurotrauma consultant who evaluated Tagovailoa after he stumbled off the field against Buffalo on Sept. 25 following a hit. The quarterback was evaluated for a concussion, but he quickly returned to the game and the Dolphins said a back injury had caused his wobbly gait.

    The quarterback subsequently suffered a concussion four days later at Cincinnati and is out indefinitely.

    Goodell, without citing Tagovailoa by name, said there’s “more chatter now” about concussions.

    “We understand some of that chatter, but the reality is the protocols are really important. We follow that strictly. We see no indication that that didn’t happen in this case. There’s an ongoing investigation, ” he said. “We’re really focused on doing that. But we’re also prepared to make a change or two in the protocols because we think we can actually add another element that would make it even safer.”

    On Friday, the NFL Players Association urged the league to implement changes in time to protect players in this weekend’s games. In its own statement, the NFL said it was working on updates to the protocol but did not commit to implementing them before Sunday’s games.

    Tampa Bay Buccaneers tight end Cameron Brate’ was also injured last Sunday when he collided with a teammate near the end of the first half against the Kansas City Chiefs and was initially allowed to re-enter the game. He then sat out the second half with a concussion.

    NFL players “are getting the most extraordinary care and better than they ever have in the history of the NFL, but they deserve that, and that’s our obligation, and that’s what we need to do,” Goodell said.

    [ad_2]

    Source link

  • Afraid of heights, he climbed Mount Everest — now he’s helping others conquer their fears too

    Afraid of heights, he climbed Mount Everest — now he’s helping others conquer their fears too

    [ad_1]

    Vivian James Rigney is no casual traveler.

    The executive coach and speaker has visited more than 80 countries and lived on three continents.

    He’s also climbed the highest mountains on all seven continents, the so-called Seven Summits.

    It’s a feat that took him 14 years — one, he estimates, that fewer than 1,000 people have completed.

    And he did it despite being “terrified of heights,” he said.

    In an interview with CNBC Travel, Rigney talked about what he learned — and how much it cost him — to reach some of the highest points on earth.  

    The cost to climb

    Rigney estimates he’s paid between $170,000 and $180,000 to climb the Seven Summits, he said.

    “Everest is, by far, the most expensive,” he said, adding that he paid about $80,000 when he climbed it in 2010.

    “You have to save and build a plan,” he said. “That’s why it took me years. I started, then I went to business school, all my money was gone into that, then I started again, got a new job … Piece by piece, I gradually got through it.”

    But there’s another cost — the time away from work, said Rigney. Luckily, he said his employers supported his goals.

    “If you have a good employer … they can see [personal goals] as something which can help lift the spirits of the company,” he said.

    From ‘easy’ to ‘excruciatingly painful’  

    In addition to costs, the Seven Summits vary considerably in terms of climbing difficulty, said Rigney.  

    He said Africa’s Mount Kilimanjaro is “easy,” calling it “technically not challenging at all.”

    But it is high enough to feel altitude sickness, he said, which stops some climbers from reaching the top.

    Kilimanjaro can be climbed in a week, he said. Antarctica’s Vinson Massif can take two weeks — “if you’re lucky” — and North America’s Denali three to four weeks.

    But Mount Everest is a “massive logistical operation” that takes about two months, he said. It’s by far the most difficult and dangerous climb, he said, calling the experience “excruciatingly painful.”  

    “Every cell in your body is saying you shouldn’t be here,” he said. “Your intuition is going nuts.”

    Rigney climbed Mount Everest for about four to five hours a day. The rest of the time “you’re recovering in your tent alone … no devices, no internet … nothing.”

    Courtesy of Inside Us LLC

    He said he arrived “bulked up and super fit.” Despite consuming 7,000 to 8,000 calories a day — mainly potatoes, pasta and dry food — he said he lost 20 pounds during the Everest climb.

    Staying warm takes a tremendous amount of energy, he said. Everything freezes, he said, including LCD camera screens.

    “We have what we call a pee bag. You pee in this bag, and you seal it and you put that into the sleeper bag with you because it’s warm.”

    There are only about three to five days in the climbing season that climbers can reach Everest’s summit. If they do, it’s a quick victory, said Rigney.

    “People don’t hang around the summit for hours,” he said. “You get the heck off the mountain as quick as you can.”

    From climbing to coaching

    Rigney is now an executive coach and speaker, teaching corporate executives lessons he learned from pushing himself, mentally and physically, to the limit.

    He’s also the author of “Naked at the Knife’s Edge,” a book about how he’s used some of the most harrowing moments from his Everest climb for professional success.

    Climbers don’t stay long once they reach Mount Everest’s peak, said Rigney. “You get the heck off the mountain as quick as you can.”

    Courtesy of Inside Us LLC

    He said he helps “overachievers… [with] tons on their mind” achieve balance and break habits “which pull us along … as though we’re on a conveyor belt.”

    For example, fear — whether it’s of public speaking or his own fear of heights — can be overcome using tricks of the mind, he said.

    And leaders must learn to accept things that are out of their control, be it an injury or a pandemic, he said.  

    He said he still laughs when he thinks about arriving at a small airplane hangar in Kathmandu one hour before he was scheduled to fly to the foothills of the Himalayas.

    After climbing the “Seven Summits,” Rigney said he is deliberately choosing travel experiences that are less risky. He said several years ago, he found a hobby that is both challenging and fun: scuba diving.

    Courtesy of Inside Us LLC

    “I remember going up to this gentleman … and I said ‘Hey… what time do you think we’ll be leaving?’” said Rigney. “He said: ‘Maybe today, hopefully by tomorrow, likely by the end of the week.’”

    Ten minutes later, another climber, who got the same answer, exploded with anger, he said.  

    “Eventually this guy looks over, red with steam coming out his ears, and we are just howling. I think it finally clicked — like this is where you are. This is about weather in the Himalayas!”

    It’s just one of a long list of “things we can control and things we cannot,” said Rigney.

    [ad_2]

    Source link

  • U.S. will screen people arriving from Uganda for Ebola as East African nation battles outbreak

    U.S. will screen people arriving from Uganda for Ebola as East African nation battles outbreak

    [ad_1]

    The U.S. will rout and screen passengers for Ebola at five designated airports if they have traveled in Uganda within three weeks prior to their arrival, federal officials said on Thursday.

    Uganda, a nation in East Africa, is battling a deadly outbreak of Ebola with 63 confirmed and probable cases and 29 deaths, according to the World Health Organization. No cases of Ebola have been reported in the U.S., according to the Centers for Disease Control and Prevention.

    The CDC is working closely with Uganda’s health ministry and the WHO to respond to the outbreak.

    The U.S. Embassy in Uganda, in a health alert Thursday, said passengers who have been in the East African nation within 21 days of their arrival in the U.S. will be routed to one of five airports: New York JFK, Newark, Atlanta, Chicago O’Hare or Washington Dulles.

    Passengers arriving from Uganda at those airports will undergo temperature checks and verification of their contact data, a federal health official said. Airlines will send passenger information to the Centers for Disease Control and Prevention so the agency can conduct health follow ups, the official said. Contact information will also be sent to state health departments so they can conduct follow ups locally.

    Uganda is battling an outbreak caused by a strain of Ebola called Sudan ebolavirus. The virus spreads through direct contact with body fluids of a person who has fallen ill with the virus or died from it, as well as infected animals and contaminated objects, according to CDC. Ebola does not spread through airborne transmission, the health agency said.

    People infected with ebolavirus are not contagious until symptoms appear, which can take anywhere from two to 21 days after contact with the virus, according to CDC. On average, it takes about 8 to 10 days for symptoms to appear.

    Symptoms include unexplained hemorrhaging, bleeding or bruising; fever; severe headache and muscle and joint pain; stomach pain, diarrhea and vomiting. Other symptoms include red eyes, skin rash and hiccups.

    There is no vaccine licensed by the Food and Drug Administration to protect against the Sudan ebolavirus strain. The FDA approved a vaccine to combat Zaire ebolavirus based on animal studies, but it’s not expected to protect against the Sudan strain, according to CDC. There is also no FDA approved treatment for Sudan ebolavirus.

    The CDC, in a health alert Thursday, said health-care providers should be on the alert for any patients suspected of having Ebola. Physicians and other clinicians should obtain a detailed travel history for any patients suspected of having the disease, particularly for people who have been to the regions in Uganda where there is an outbreak.

    This is breaking news. Please check back for updates.

    [ad_2]

    Source link

  • Monkeypox eradication unlikely in the U.S. as virus could spread indefinitely, CDC says

    Monkeypox eradication unlikely in the U.S. as virus could spread indefinitely, CDC says

    [ad_1]

    The monkeypox virus is unlikely to be eliminated from the U.S. in the near future, according to a report published by the Centers for Disease Control and Prevention this week.

    The CDC, in a technical brief, said the outbreak is slowing as the availability of vaccines has increased, people have become more aware of how to avoid infection, and immunity has likely increased among gay and bisexual men, the group most impacted by the virus.

    But low-level transmission of the virus could continue indefinitely among men who have sex with other men, according to the report. The CDC said it does not have a projection of how many total people might get infected by the virus.

    The Biden administration declared a public health emergency in August in an effort to ramp up vaccines, testing, treatment and community outreach in an effort to eradicate the virus from the U.S.

    The U.S. is trying to contain the largest monkeypox outbreak in the world, with nearly 26,000 cases reported across all 50 states, Washington D.C., and Puerto Rico, according to CDC data. At least two people have died from the disease in the U.S., according to the data.

    The global monkeypox outbreak, the largest in history, is highly unusual because the virus is circulating widely in countries where it is not normally found. Historically, monkeypox has circulated in remote parts of West and Central Africa. In that context, people normally caught the virus from animals. There was little spread between people.

    Monkeypox is now spreading widely between people, mostly through close contact during sex among gay and bisexual men. The disease is rarely fatal, but patients develop lesions resembling blisters in sensitive areas that are extremely painful. In some cases, the pain is so great people require hospitalization and in rare instances people with weak immune systems have died.

    The CDC, in its report, said the virus is still spreading primarily among men who have sex with men. But anyone can catch the virus through close contact with someone who is infected or with contaminated materials. Health authorities have confirmed 29 cases of children catching the virus to date, and 78 total pediatric cases are under investigation as of late September.

    Though 96% of patients are men, 408 women have caught the virus to date in the U.S. Four pregnant women and one who was breastfeeding have caught monkeypox.

    The CDC said the percentage of patients who identify as gay or bisexual men has declined over time, with 75% of people who provided recent sexual history reporting male-to-male contact.

    But a large number of cases are missing data on sexual history and more than 90% of infections are among males, according to CDC. The decline in the percentage of cases reporting male-to-male sexual contact is likely due to missing data rather than a change in how the virus is spreading, according to the public health agency.

    The CDC said the outbreak will likely remain concentrated among men who have sex with men over the long term, with infections continuing to decline over the coming weeks and dropping significantly over the next several months.

    More than 684,000 people have received the Jynneos monkeypox vaccine so far. Earlier this week, the CDC reported preliminary data indicating that the vaccine is providing at least some protection against infection. The vaccination campaign is primarily focused on gay and bisexual men.

    The outbreak could start accelerating again if the virus starts spreading widely among the U.S. population through heterosexual networks or contact that doesn’t involve sex, according to CDC. But there is no country in the current global outbreak that has found clear evidence of sustained spread of the virus outside sexual networks of gay and bisexual men, according to the CDC.

    The public health agency also warned that the virus could start spreading faster again among people if it becomes established in an animal population in the U.S. The CDC said it is unknown which animals in North America are most susceptible to infection.

    In Africa, the virus mostly spread from animals to people. If monkeypox becomes established in animals in the U.S., it would be very difficult to eradicate.

    [ad_2]

    Source link